What is B. Riley’s Estimate for TRVI Q1 Earnings?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Equities research analysts at B. Riley issued their Q1 2026 earnings per share estimates for Trevi Therapeutics in a report released on Monday, November 17th. B. Riley analyst M. Mamtani anticipates that the company will earn ($0.14) per share for the quarter. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. B. Riley also issued estimates for Trevi Therapeutics’ Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.17) EPS and Q4 2026 earnings at ($0.20) EPS.

Several other equities analysts have also weighed in on the company. Needham & Company LLC cut their target price on Trevi Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Oppenheimer raised their price objective on Trevi Therapeutics from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Wednesday, October 8th. Morgan Stanley increased their price target on Trevi Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Friday. Finally, Leerink Partners reissued an “outperform” rating and issued a $16.00 price target on shares of Trevi Therapeutics in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.44.

Trevi Therapeutics Trading Down 0.4%

TRVI stock opened at $11.31 on Wednesday. The firm has a market cap of $1.45 billion, a PE ratio of -30.57 and a beta of 0.67. Trevi Therapeutics has a 1 year low of $2.36 and a 1 year high of $12.30. The company has a fifty day simple moving average of $10.04 and a 200 day simple moving average of $7.91.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.02.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Alliancebernstein L.P. lifted its holdings in shares of Trevi Therapeutics by 19,064.5% during the second quarter. Alliancebernstein L.P. now owns 4,281,355 shares of the company’s stock worth $23,419,000 after buying an additional 4,259,015 shares during the last quarter. Rubric Capital Management LP increased its position in Trevi Therapeutics by 88.0% during the second quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company’s stock worth $46,669,000 after acquiring an additional 3,993,325 shares during the period. Viking Global Investors LP increased its position in Trevi Therapeutics by 232.4% during the third quarter. Viking Global Investors LP now owns 5,128,875 shares of the company’s stock worth $46,929,000 after acquiring an additional 3,585,875 shares during the period. Octagon Capital Advisors LP acquired a new position in Trevi Therapeutics during the 1st quarter valued at $20,895,000. Finally, Wellington Management Group LLP boosted its holdings in Trevi Therapeutics by 1,792.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,253,888 shares of the company’s stock valued at $29,773,000 after purchasing an additional 3,081,906 shares during the period. 95.76% of the stock is owned by institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.